Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 9/20 | 0.46 |
| ▸ | TEC | P42680 | 3/20 | 0.46 |
| ▸ | KRAS | P01116 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22866412 | 0.92 | EGFR (0.52) | EGFRERBB2KRASPDE4APDE4B | |
| SCHEMBL22174104 | 0.87 | EGFR (0.49) | EGFRERBB2BTKTECKRAS | |
| SCHEMBL22174268 | 0.86 | BTK (0.52) | EGFRERBB2BTKTECMKNK1 | |
| SCHEMBL22174274 | 0.86 | EGFR (0.46) | EGFRERBB2BTKTEC | |
| SCHEMBL22196877 | 0.84 | EGFR (0.48) | EGFRERBB2BTKKRASEPHX2 | |
| SCHEMBL22173960 | 0.83 | EPHX2 (0.56) | EGFRERBB2PDE4BEPHX2 | |
| SCHEMBL22173942 | 0.83 | EGFR (0.49) | EGFRERBB2BTKKRASEPHX2 | |
| SCHEMBL22174141 | 0.82 | EGFR (0.49) | EGFRERBB2KRASEPHX2 | |
| SCHEMBL22174272 | 0.82 | EGFR (0.46) | EGFRERBB2BTKTEC | |
| SCHEMBL22866410 | 0.82 | PDE4B (0.56) | EGFRERBB2BTKTECPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771689-B2 | Cereblon modulators and uses thereof | VIVIDION THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11771689-B2 | Cereblon modulators and uses thereof | VIVIDION THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20220298213-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | VIVIDION THERAPEUTICS, INC. | 2022-09-22 | — | — | US | disclosed |
| US-10869860-B2 | Cereblon modulators and uses thereof | VIVIDION THERAPEUTICS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-10781239-B2 | In vivo engineered cereblon protein | VIVIDION THERAPEUTICS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200206201-A1 | CEREBLON MODULATORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298213-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | EGFR 4245/4885ERBB2 4374/4885BTK 3352/4885 |
| US-11771689-B2 | Cereblon modulators and uses thereof | CRBN, CBFB, CNN2 | EGFR 1232/4885ERBB2 3488/4885BTK 649/4885 |
| US-10869860-B2 | Cereblon modulators and uses thereof | CRBN, CBFB, CNN2 | EGFR 1232/4885ERBB2 3488/4885BTK 649/4885 |
| US-20200206201-A1 | CEREBLON MODULATORS AND USES THEREOF | CRBN, CBFB, CNN2 | EGFR 1232/4885ERBB2 3488/4885BTK 649/4885 |
| US-10781239-B2 | In vivo engineered cereblon protein | CRBN, CDR2, DCUN1D4 | EGFR 4245/4885ERBB2 4374/4885BTK 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.